Abstract
We investigated the contractile role of M2 muscarinic receptors in mouse urinary bladder. When measured in the absence of other agents, contractions elicited to the muscarinic agonist oxotremorine-M exhibited properties consistent with that expected for an M3 response in urinary bladder from wild-type and M2 knockout (KO) mice. Evidence for a minor M2 receptor-mediated contraction was revealed by a comparison of responses in M3 knockout and M2/M3 double knockout mice. Treatment of wild-type and M2 knockout urinary bladder with N-2-chloroethyl-4-piperidinyl diphenylacetate (4-DAMP mustard) caused a large inhibition of the muscarinic contractile response. The residual contractions were much smaller in M2 knockout bladder compared with wild type, suggesting that M2 receptors rescue the muscarinic contractile response in wild-type bladder following inactivation of M3 receptors with 4-DAMP mustard. When measured in the presence of prostaglandin F2α and isoproterenol or forskolin, oxotremorine-M mediated a potent contractile response in urinary bladder from M3 KO mice. This response exhibited an M2 profile in competitive antagonism studies and was completely absent in M2/M3 KO mice. Following 4-DAMP mustard treatment, oxotremorine-M elicited a contractile response in wild-type urinary bladder in the presence of KCl and isoproterenol or forskolin, and this response was diminished in M2 KO mice. Our results show that the M2 receptor mediates contractions indirectly in the urinary bladder by enhancing M3 receptor-mediated contractions and inhibiting relaxation. We also show that it is difficult to detect M2 receptor function in competitive antagonism studies under conditions where a simultaneous activation of M2 and M3 receptors occurs.
Footnotes
-
This work was supported by a grant from Pfizer (F.J.E.); grants-in-aid for Scientific Research from the Ministry of Education, Science, Sports and Culture (M.M., M.M.T.); Industrial Technology Research Grant Program in 2000 and 2002 from the New Energy and Industrial Technology Development Organization of Japan (M.M.); Health and Labor Sciences Research grants on Research on Measures for Intractable Diseases from Ministry of Health, Labor and Welfare of Japan (M.M.); and a grant from the Organization for Pharmaceutical Safety and Research, Tokyo, Japan (M.M.T.).
-
Article, publication date, and citation information can be found at http://jpet.aspetjournals.org.
-
doi:10.1124/jpet.104.077909.
-
ABBREVIATIONS: KO, knockout; 4-DAMP mustard, N-2-chloroethyl-4-piperidinyl diphenylacetate; KRB, Krebs-Ringer bicarbonate; AF-DX 116, [[2-[(diethylamino) methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3b][1,4]-benzodiazepine-6-one; PGF2α, prostaglandin F2α; 4-DAMP, N,N-dimethyl-4-piperidinyl diphenylacetate.
-
↵1 Current address: Division of Neuronal Network, Department of Basic Medical Sciences, The Institute of Medical Science, The University of Tokyo, Minato-ku, Tokyo, Japan.
- Received September 14, 2004.
- Accepted November 11, 2004.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|







